<DOC>
	<DOC>NCT01266655</DOC>
	<brief_summary>There is first evidence from preclinical and clinical studies for the efficacy of the selective GABA-B receptor agonist baclofen in the treatment of alcohol dependence. The aim of this trial is to evaluate the efficacy and safety of individually titrated high-dose baclofen for relapse prevention in alcohol-dependent patients.</brief_summary>
	<brief_title>Baclofen for the Treatment of Alcohol Dependence</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<criteria>Diagnosis of alcohol dependence according to ICD10 (International Classification of Mental and Behavioural Disorders, 10th revision) and DSMIV (Diagnostic and Statistical Manual of Mental Disorders, 4th revision) criteria An alcohol intake of at least two heavy drinking days per week on average (men ≥ 5 drinks per day; women ≥ 4 drinks per day) and an average overall consumption of 21 drinks per week or more for men and 14 drinks per week or more for women during the 4 weeks before detoxification (one standard drink is equal to 12 g absolute alcohol) Last alcohol consumption within 721 days before randomisation Sufficient German language capabilities Pregnancy and/or currently breastfeeding Clinical significant medical conditions or observed abnormalities Psychiatric illness undergoing treatment with psychoactive drugs Epilepsy or epileptiform convulsions Addiction to drugs other than nicotine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>